Lung Cancer
Conference Coverage
Rare, aggressive NSCLC type yields to pembrolizumab
SAN FRANCISCO – Pulmonary sarcomatoid carcinoma tumors have high mutational burden and PD-L1 expression, making them ideal targets for immune...
Conference Coverage
NILE: Liquid biopsy bests tissue testing for targetable mutations in NSCLC
Liquid biopsy was more effective and faster than tissue-based genotyping for identifying targetable mutations in advanced NSCLC in the prospective...
From the Journals
Caring for aging HIV-infected patients requires close attention to unrelated diseases
From the Journals
SABR response rate falls short in early NSCLC
In a phase 2 trial of patients with resectable stage I NSCLC, stereotactic ablative radiotherapy provided a lower than expected pCR of 60%, and...
From the Journals
Checkpoint inhibitors ‘viable treatment option’ in HIV-infected individuals
There were no concerning immune-mediated toxicities or changes in HIV-related parameters observed among 73 patients with HIV infection who had...
Conference Coverage
Enoblituzumab plus pembrolizumab shows promise for select solid tumors
WASHINGTON – Combination enoblituzumab and pembrolizumab showed acceptable safety and encouraging antitumor activity in select patients with B7-H3...
Feature
Lifetime cost of tobacco use tops $1.9 million per smoker
Connecticut’s estimated cost is more than twice as high as Georgia’s.
Conference Coverage
The personal cancer vaccine NEO-PV-01 shows promise in metastatic cancers
WASHINGTON – The NEO-PV-1 neoantigen vaccine plus poly-ICLC adjuvant and nivolumab is well tolerated and shows clinical activity in metastatic...
From the Journals
HBV, HCV, HIV testing of new cancer patients advised
Many patients with newly diagnosed cancers were unaware of their infection status, and some had no known risk factors.
From the Journals
Self-reporting extends lung cancer survival
Patients with nonprogressive, metastatic lung cancer who report symptoms through a weekly, web-based monitoring system may survive longer than...
From the Journals
Platinum-etoposide, taxanes best for small cell transformed EGFR-mutant lung cancer
Both platinum-etoposide and taxane therapies produced high response rates (71% each), but patients did not respond to checkpoint inhibitor therapy...